In the news
Vilya Founder Dr. David Baker Awarded the 2024 Nobel Prize in Chemistry
Our scientific founder, Dr. David Baker, has been awarded the 2024 Nobel Prize in Chemistry for his pioneering work in computational protein design. The science behind Vilya’s mission builds directly upon Dr. Baker’s original discovery by applying advanced computational approaches to design novel, chemically diverse macrocycles to target disease biology with unprecedented precision.
LEARN MORE ABOUT OUR FOUNDATIONAL SCIENCE
6/4/2024
Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines
MORE NEWS
3
4/25/2024
Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles
7
08/30/2022
Fierce Biotech: Arch builds bridge to new class of medicines, leading $50M investment in the AI-enabled Vilya
8
08/29/2022
Vilya launches to design a new transformational class of medicines that precisely target disease biology
10
08/29/2022
UW Institute for Protein Design: Design of membrane-traversing peptides leads to new spinout
11
08/29/2022
David Baker’s lab and ARCH sprout Lord of the Rings-inspired macrocycle biotech
12
08/29/2022
Timmerman Report: Arch Bets $50M on Vilya, Baker Lab Spinout to Make Targeted, Oral Peptide Drugs
13
